Tomocube

Founded in 2015, Tomocube is an optics-and-AI-based 3D cell imaging company whose core capability is holotomography (HT) technology, which analyzes living cells and organoids in real-time 3D without staining or sectioning.

The company's technology relies on inverse reconstruction of 3D structure from light diffraction analysis, using a digital micromirror device (DMD) to accurately reproduce object shapes even with a fixed light source.

Its product lineup has evolved from the first-generation HT-1H and HT-2H to the second-generation HT-X1, a lower-cost HT-X1 mini, and a premium HT-X1 Plus, with a next-generation flagship HT-X1 Max featuring enhanced measurement performance scheduled for launch in 2026.

Its customer base began with bio research equipment sales to universities and hospitals and has expanded through joint research with institutions such as EPFL and Johns Hopkins as well as global pharmaceutical companies.

More recently the company has broadened into industrial (non-bio) inspection modules for semiconductor and display precision measurement, signing a module supply agreement with ELP in 2024.

According to Leading Investment & Securities, Tomocube's holotomography technology has been described as cutting measurement time in existing hybrid bonding processes from two minutes to one second.

The company is also pairing AI-based phenotype analysis software with a subscription (SaaS) model in an effort to build recurring revenue on top of equipment sales. It maintains direct sales rather than a dealer network, aiming to manage both brand value and profitability.

Competitively, the company claims a technological edge in resolution and stability over first-generation laser-based rivals, and the market sometimes compares it to Park Systems, a semiconductor metrology company, given that Park Systems' CEO serves as one of Tomocube's outside directors.

Tomocube's annual revenue rose sharply from KRW 3.75 billion in 2023 to KRW 5.94 billion in 2024 and KRW 11.31 billion in 2025, yet operating losses persisted at KRW 6.73 billion, KRW 8.78 billion, and KRW 5.57 billion over the same period.

Still, the 2025 operating margin of -49.3% marked a notable improvement from -147.8% in 2024 and -179.7% in 2023.

On a quarterly basis, losses actually widened in 2Q25 (revenue KRW 3.14 billion, operating loss KRW 1.13 billion) and 3Q25 (revenue KRW 2.52 billion, operating loss KRW 1.83 billion), before revenue surged to KRW 4.99 billion in 4Q25, delivering an operating profit of KRW 0.40 billion and owners' net income of KRW 0.64 billion—the company's first quarterly profit since listing.

However, revenue fell back to KRW 2.75 billion in 1Q26, and the operating loss widened again to KRW 1.87 billion, echoing the seasonality management had flagged at its corporate day, where fourth-quarter revenue concentration and first-quarter softness were described as a recurring pattern.

In 2Q26, revenue recovered to KRW 4.96 billion, close to the 4Q25 level, while the operating loss narrowed considerably to KRW 0.59 billion and the owners' net loss to KRW 0.20 billion.

As a result, the cumulative owners' net loss over the most recent four quarters (3Q25 through 2Q26) stood at KRW 2.45 billion, showing that while quarter-to-quarter volatility remains high, the loss magnitude has gradually narrowed on a rolling basis.

On the balance sheet, the company maintains a low-leverage structure with almost no net debt; the debt ratio fell from 11.7% in 2023 to 3.9% in 2024 before rising modestly to 7.0% in 2025.

Operating cash flow, however, was negative at KRW -5.93 billion, KRW -6.54 billion, and KRW -6.75 billion in 2023, 2024, and 2025 respectively, meaning cash outflow actually widened slightly even as revenue grew, reflecting continued investment and operating spending tied to growth.

Owners' equity jumped from KRW 17.71 billion in 2023 to KRW 41.99 billion in 2024, largely due to IPO-related capital inflows, before declining slightly to KRW 38.79 billion in 2025 as accumulated losses were reflected.

The holotomography-based 3D cell imaging market that Tomocube operates in is growing on the back of two structural shifts: the move away from animal testing and the industrialization of organoid research. The paradigm shift toward New Approach Methodologies (NAM) championed by the U.S.

FDA is driving increased demand for three-dimensional human models such as organoids, and Charles River Laboratories, the world's largest contract research organization, has been described as pursuing a strategy responsive to this trend.

Brokerage estimates have put Tomocube's addressable market at roughly KRW 7.6 trillion combined across South Korea, the United States, Europe, and China, with the U.S. and Europe accounting for the largest shares.

Competitively, the company is often compared against overseas suppliers of first-generation laser-based holotomography equipment, and Tomocube emphasizes its LED multi-light-source approach and improved measurement depth as points of technical differentiation.

Daishin Securities assessed that Tomocube is currently the only supplier capable of non-destructive quantitative analysis of thick 3D samples, citing its unique position in large-organoid analysis as an investment point.

In the industrial (non-bio) metrology market, demand for non-destructive 3D internal inspection is growing in areas such as semiconductor hybrid bonding and display/glass substrate inspection, though this remains a relatively new area for Tomocube where reference cases are still being accumulated.

Overall, the industry remains in an early growth phase, and the pace of standardization, regulatory approval, and reference-building is likely to be a key determinant of individual companies' market share gains.

The company has guided to full-year 2026 revenue of at least KRW 16.4 billion and has set a break-even point (BEP) as its target.

Tomocube CFO Ku Wan-sung stated this goal at a corporate day held in late March, expressing confidence in reaching the guidance based on revenue growth from KRW 5.9 billion in 2024 to KRW 11.3 billion in 2025.

The company plans to launch a new flagship model, the HT-X1 Max, this year; while the launch was somewhat delayed due to ongoing testing with a global pharmaceutical partner, management said the within-year launch timeline remains unchanged.

The HT-X1 Max is described as offering maximum resolution of 124nm and a measurement depth of up to 500 micrometers, more than double the performance of the prior second-generation product.

In the industrial (non-bio) segment, collaboration with partners is underway including in the semiconductor wafer field, and the company has said it expects more than KRW 5 billion in revenue from the non-bio segment alone this year.

Some brokerages have flagged the disclosure of ultra-high-end equipment data in 3Q26 and the HT-X1 Max launch along with entry into industrial quality testing in 4Q26 as potential future catalysts, though these remain analyst expectations rather than confirmed schedules.

Still, as shown by the return to an operating loss in 1Q26, whether the annual guidance is met will depend on how much second-half industrial and bio revenue materializes.

Management itself has acknowledged that revenue carries seasonality, tending to concentrate in the fourth quarter with relative softness in the first quarter, suggesting that quarterly swings should be assessed within a full-year context.